Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06299098 · ClinicalTrials.gov registry record · Phase 2
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
A Phase 2 study of Obesity, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 1,005
- Enrollment target
- 20
- Study locations
NCT06299098 is a Phase 2 study of Obesity that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 1,005 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (23% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT06299098, a Phase 2 study of Obesity, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,005 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity. The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B and Part C of the study is to see how safe and effective the study drug is when combined with Wegovy. Parts A, B, and C of the study are looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG Semaglutide
- DRUG Garetosmab
- DRUG Trevogrumab-Part A
- DRUG Trevogrumab-Part B and Part C
- DRUG Matching Placebo-Part A
Study Locations (20)
California
- Anaheim Clinical Trials - Anaheim
- ProSciento - Chula Vista
- Valiance Clinical Research- Huntington Park - Huntington Park
- Velocity, San Diego - La Mesa
- Northern California Research - Sacramento
- Acclaim Clinical Research - San Diego
- Metabolic Institute of America - Tarzana
- Valiance Clinical Research - Tarzana
Florida
- Southwest General Healthcare Center - Fort Myers
- Westside Center for Clinical Research - Jacksonville
- Jacksonville Center for Clinical Research - Jacksonville
- IMA Clinical Research St. Petersburg - St. Petersburg
- Precision Clinical Research, LLC - Sunrise
- Clinical Research of West Florida, Inc. - Tampa
- Clinical Research of Central Florida - Bond Clinic - Winter Haven
Alabama
- Pinnacle Research Group - Anniston
- Cullman Clinical Trials - Cullman
Georgia
- Center for Advanced Research and Education - Gainesville
- Balanced Life Health Care Solutions - Lawrenceville
Arizona
- Foothills Research Center Cct Research - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,005 participants |
| Start Date | 2024-03-13 |
| Est. Completion | 2026-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06299098
The ClinicalTrials.gov registry entry for NCT06299098 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 1,005 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (23% higher). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 5 interventions - of which Semaglutide is the first listed.
NCT06299098 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06299098 about?
NCT06299098 is a clinical study titled "A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation". This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the study is focused on...
What is the current status of trial NCT06299098?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,005 participants. The study started on 2024-03-13. Estimated completion is 2026-10-30.
What conditions does trial NCT06299098 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06299098?
The interventions under investigation include: Semaglutide (DRUG), Garetosmab (DRUG), Trevogrumab-Part A (DRUG), Trevogrumab-Part B and Part C (DRUG), Matching Placebo-Part A (DRUG).
Who is sponsoring clinical trial NCT06299098?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06299098 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.